Abstract: Objective To systematically review the efficacy and safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in the third trimester of pregnancy. Methods Chinese Biomedical Literature Database,WanFang Database Online,Chinese Scientific Journals Database,CNKI,PubMed,ISI web of knowledge,EMBASE,Cochrane Library and BIOSIS Previews were searched for related articles till September 2013. Two reviewers independently screened these articles according to inclusion and exclusion criterion. Meta-analysis was performed by using software Rvman 5.1. Results Eleven papers were included in this study,with a total of 1241 pregnant women,including 602 cases received telbivudine and 639 cases of control;Meta-analysis showed that, after a 6 to 12 month of follow-up,the seropositive rates for HBsAg and HBV DNA in babies of telbivudine-treated mothers were significantly lower than in babies of non-treated mothers[RR=0.15,95%CI（0.08,0.28）,P<0.00001;RR=0.12,95%CI（0.05,0.32）,P<0.0001,respectively];Maternal HBV DNA levels prior to delivery was significantly lower in telbivudine-treated women than in non-treated women[MD=-3.86,95%CI（-4.55,-3.16）,P<0.00001];The rate of elevation in serum creatine kinase （CK） was significantly higher in telbivudine-treated mothers than in non-treated mothers[MD=-3.86,95%CI（-4.55,-3.16）,P<0.00001];The neonates in telbivudine group were born without deformity and other complications. Conclusion Telbivudine is effective and safe in blocking HBV intrauterine infection.

Key words: Hepatitis B, Telbivudine, Intrauterine transmission, Pregnancy, Meta analysis